Eli Lilly and Company (NYSE:LLY) Stock Price Down 1.4% Following Analyst Downgrade

Eli Lilly and Company (NYSE:LLY) fell 1.4% during trading on Wednesday after HSBC downgraded the stock from a hold rating to a reduce rating. HSBC now has a $850.00 price target on the stock, down from their previous price target of $1,070.00. Eli Lilly and Company traded as low as $905.11 and last traded at $916.8760. 3,431,348 shares traded hands during mid-day trading, an increase of 7% from the average session volume of 3,220,997 shares. The stock had previously closed at $930.35.

LLY has been the topic of several other research reports. TD Cowen raised their price objective on shares of Eli Lilly and Company from $960.00 to $1,250.00 and gave the stock a “buy” rating in a report on Thursday, January 29th. Barclays started coverage on shares of Eli Lilly and Company in a research report on Thursday, February 19th. They issued an “overweight” rating and a $1,350.00 price target for the company. JPMorgan Chase & Co. raised their price target on shares of Eli Lilly and Company from $1,150.00 to $1,300.00 and gave the stock an “overweight” rating in a research note on Thursday, February 5th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a report on Tuesday, February 10th. Finally, Truist Financial reiterated a “buy” rating on shares of Eli Lilly and Company in a research note on Monday, February 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,221.44.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: New research suggesting that stopping GLP‑1 therapy raises cardiovascular risks supports continued demand and adherence for drugs like Mounjaro/Zepbound, reinforcing the long‑term revenue case for Lilly. Read More.
• Positive Sentiment: Lilly is investing heavily in production capacity — a $1.8B upgrade to Indianapolis operations and a planned $3.5B plant in Pennsylvania — which should support supply for fast‑growing obesity/diabetes franchises. These capex moves point to management preparing for sustained volume growth. Read More. Read More.
• Positive Sentiment: Several sell‑side firms remain bullish (Bernstein, SocGen, Goldman/etc.), citing GLP‑1 expansion and distribution initiatives (e.g., Employer Connect), which underpins multi‑quarter growth expectations for LLY. Read More.
• Neutral Sentiment: Analysts and commentators note that Lilly’s rivalry with Roche/Novo and new tech/partnership dynamics are intensifying — constructive for market leadership but adding competitive complexity. Read More.
• Neutral Sentiment: Technical/market commentators say the stock looks oversold after the sell‑off and may be approaching a support zone—this frames a potential tactical buying opportunity if fundamentals hold. Read More.
• Negative Sentiment: HSBC downgraded LLY to “Reduce” (cutting its PT from $1,070 to $850), citing U.S. pricing pressure, rising competition in the obesity market and what it sees as over‑optimistic obesity revenue forecasts — the downgrade sparked heavy selling and headline risk. Read More. Read More.
• Negative Sentiment: Regulatory and competitive catalysts remain watch‑points — recent coverage highlights FDA decisions, potential oral‑pill pricing dynamics and intensified rivalry with Novo Nordisk, any of which could compress near‑term growth or margins. Read More.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LLY. 10Elms LLP raised its stake in Eli Lilly and Company by 33.3% during the 3rd quarter. 10Elms LLP now owns 40 shares of the company’s stock worth $31,000 after buying an additional 10 shares during the period. M.E. Allison & CO. Inc. grew its stake in Eli Lilly and Company by 0.7% in the fourth quarter. M.E. Allison & CO. Inc. now owns 1,477 shares of the company’s stock valued at $1,587,000 after acquiring an additional 10 shares during the period. Tanager Wealth Management LLP grew its stake in Eli Lilly and Company by 2.6% in the fourth quarter. Tanager Wealth Management LLP now owns 395 shares of the company’s stock valued at $424,000 after acquiring an additional 10 shares during the period. Morey & Quinn Wealth Partners LLC increased its holdings in shares of Eli Lilly and Company by 1.5% in the fourth quarter. Morey & Quinn Wealth Partners LLC now owns 661 shares of the company’s stock worth $710,000 after acquiring an additional 10 shares in the last quarter. Finally, Wealthspan Partners LLC increased its holdings in shares of Eli Lilly and Company by 0.5% in the fourth quarter. Wealthspan Partners LLC now owns 2,110 shares of the company’s stock worth $2,268,000 after acquiring an additional 10 shares in the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Trading Down 1.4%

The business’s fifty day moving average is $1,033.54 and its 200 day moving average is $955.52. The firm has a market capitalization of $866.28 billion, a price-to-earnings ratio of 39.95, a price-to-earnings-growth ratio of 1.15 and a beta of 0.40. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The business had revenue of $19.29 billion during the quarter, compared to analysts’ expectations of $17.85 billion. During the same quarter in the prior year, the company posted $5.32 earnings per share. The firm’s revenue was up 42.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Equities analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current year.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.